CINGULATE INC(NASDAQ:CING) stock News

CING Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: The Motley Fool

Cingulate Posts Wider Loss in Q2

9 days ago - By: Cingulate Inc.

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

13 days ago - By: Cingulate Inc.

Cingulate Provides Management Team Update

22 days ago - By: Cingulate Inc.

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

a year ago - By: Benzinga

How Is The Market Feeling About Cingulate?

a year ago - By: Benzinga - Mentions: LQDA ALZN SOND VRAX ...

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher

2 months ago - By: Cingulate Inc.

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

3 months ago - By: Life365

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

4 months ago - By: Cingulate Inc.

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

5 months ago - By: Cingulate Inc.

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

5 months ago - By: Cingulate Inc.

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

5 months ago - By: Cingulate Inc.

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

6 months ago - By: Cingulate Inc.

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

8 months ago - By: Cingulate Inc.

Final Study Completed for Cingulate’s Lead Asset CTx-1301

8 months ago - By: Cingulate Inc.

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

10 months ago - By: Cingulate Inc.

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

a year ago - By: Cingulate Inc.

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

a year ago - By: Cingulate Inc.

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

a year ago - By: Cingulate Inc.

Cingulate to Participate in Benzinga All Live Access Event

a year ago - By: Cingulate Inc.

CINGULATE INC (CING) Stock News

CING Latest News, Press Relases and Analysis

Cingulate Posts Wider Loss in Q2

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

How Is The Market Feeling About Cingulate?

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Final Study Completed for Cingulate’s Lead Asset CTx-1301

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting